2019
DOI: 10.1080/1744666x.2019.1561282
|View full text |Cite
|
Sign up to set email alerts
|

From mother to baby: antenatal exposure to monoclonal antibody biologics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
31
0
5

Year Published

2019
2019
2021
2021

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(36 citation statements)
references
References 77 publications
0
31
0
5
Order By: Relevance
“…It is generally thought that little anti-TNF medication crosses the placenta in the first trimester. However, there is direct and indirect evidence of placental transfer of anti-TNF-α medications in the third trimester via measurable cord blood levels even weeks after maternal discontinuation of treatment [1]. One case report suggested that adalimumab was detectable in the cord serum of an infant delivered at 37.5 weeks gestation despite the fact that the mother discontinued treatment in gestational week 16 [22].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It is generally thought that little anti-TNF medication crosses the placenta in the first trimester. However, there is direct and indirect evidence of placental transfer of anti-TNF-α medications in the third trimester via measurable cord blood levels even weeks after maternal discontinuation of treatment [1]. One case report suggested that adalimumab was detectable in the cord serum of an infant delivered at 37.5 weeks gestation despite the fact that the mother discontinued treatment in gestational week 16 [22].…”
Section: Discussionmentioning
confidence: 99%
“…Adalimumab is a fully humanized monoclonal antibody with a high molecular weight and is expected to require active transport in order to cross the human placenta. For this reason, it is thought that potential exposure of the embryo via placental transfer is limited earlier in pregnancy, while transfer to the fetus later in pregnancy has been documented [1].…”
Section: Introductionmentioning
confidence: 99%
“…The combination of tacrolimus and steroids is diabetogenic and women taking these drugs in isolation or combination should be screened for gestational diabetes. The role of intravenous immunoglobulin (IVIg) in treating immune cytopaenias is established outside of pregnancy and is safe to use in pregnancy, especially when rituximab is avoided due to the risk of neonatal B-cell depletion (see section 2) [233]. The use of IVIg is also described in case studies where infection risk precludes traditional immunosuppression [234].…”
Section: Rationale For Clinical Practice Guidelinesmentioning
confidence: 99%
“…Im Falle einer pränatalen immunsuppressiven Medikation können und sollten Impfungen mit Totimpfstoffen zeitgerecht nach STIKO-Empfehlung erfolgen [275]. Impfungen mit Lebendimpfstoffen sollten in Abhängigkeit vom gegebenen Immunsuppressivum erst bei nachgewiesenen normwertigen Lymphozyten durchgeführt werden [ExpertInnenkonsens] [372].…”
Section: Impfen Von Säuglingen Und Kindern Nach In Utero-exposition Gunclassified